Go Deep
Opus Genetics, Inc.
Opus Genetics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -32,168 | -3.3 | -27.16 | 0.07 | 403.79 |
| Oct 2026 | -31,621 | -3.2 | -26.27 | 0.07 | 389.28 |
| Oct 2026 | -31,425 | -3.3 | -25.95 | 0.07 | 384.59 |
| Oct 2026 | -30,604 | -3.0 | -24.60 | 0.07 | 363.71 |
| Oct 2026 | -30,525 | -3.0 | -24.47 | 0.07 | 362.20 |
| Oct 2026 | -31,269 | -3.2 | -25.69 | 0.07 | 380.21 |
| Oct 2026 | -31,679 | -3.2 | -26.36 | 0.07 | 389.21 |
| Oct 2026 | -30,525 | -3.0 | -24.47 | 0.07 | 360.57 |
| Oct 2026 | -29,156 | -2.7 | -22.23 | 0.07 | 328.89 |
Opus Genetics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 755,000.0 | 2,157,000.0 | 3,865,000.0 | 3,079,000.0 |
| Net Profit | -8,098,000.0 | -65,535,000.0 | -16,523,000.0 | -17,454,000.0 |
| EPS | -0.1 | -0.8 | — | -0.2 |
Opus Genetics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 14,196,000.0 | 10,992,000.0 | 19,049,000.0 | 39,850,000.0 | — |
| Net Profit | -49,591,000.0 | -57,532,000.0 | -9,986,000.0 | 17,888,000.0 | — |
| EPS | -0.8 | -2.1 | -0.5 | 0.9 | — |
Opus Genetics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 50,243,000.0 | 36,862,000.0 | 53,948,000.0 | 48,992,000.0 | — |
| Total Liabilities | 34,895,000.0 | 30,138,000.0 | 4,042,000.0 | 2,753,000.0 | — |
| Total Equity | 15,348,000.0 | 6,724,000.0 | 49,906,000.0 | 46,239,000.0 | — |
Owes vs Owns
Opus Genetics, Inc. owed $1.14 for every $1 it owned in Jun 2026, up from $0.06 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.14× | 0.69× | 0.82× | 0.07× | 0.06× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Opus Genetics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 89.7%Receivables 6.3%Other assets 3.6%
How it's funded — Dec 2025
Long-term debt 2.2%Payables 6.6%Other liabilities 60.7%Shareholders' equity 30.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 45.1 | 30.3 | 50.5 | 42.7 |
| Receivables | 3.2 | 5.8 | 2.3 | 4.8 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.2 | 0.3 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.8 | 0.5 | 1.1 | 1.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 1.1 | 0.0 | 0.0 | 0.0 |
| Payables | 3.3 | 3.1 | 2.2 | 1.1 |
| Other liabilities | 30.5 | 27.0 | 1.9 | 1.7 |
| Shareholders' equity | 15.3 | 6.7 | 49.9 | 46.2 |
| Net tangible assets | 15.3 | 6.7 | 49.9 | 46.2 |
Opus Genetics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -35,253,000.0 | -25,576,000.0 | -1,112,000.0 | 14,314,000.0 | — |
| Investing Activities | 0.0 | 1,210,000.0 | 0.0 | 0.0 | — |
| Financing Activities | 50,023,000.0 | 4,186,000.0 | 8,979,000.0 | 3,786,000.0 | — |